Indication
Von Hippel-Lindau Syndrome Gene Mutation
3 clinical trials
3 products
Clinical trial
An Open Label Phase 2 Study to Evaluate PT2385 for the Treatment of Von Hippel-Lindau Disease-Associated Clear Cell Renal Cell CarcinomaStatus: Completed, Estimated PCD: 2023-08-30
Product
PT2385Clinical trial
An Open-Label Phase 2 Study to Evaluate PT2977 for the Treatment of Von Hippel Lindau Disease-Associated Renal Cell CarcinomaStatus: Active (not recruiting), Estimated PCD: 2026-03-29
Product
BelzutifanClinical trial
Phase 1 Study of Digoxin for Congenital Erythrocytosis Due to Up-Regulated Hypoxia SensingStatus: Withdrawn, Estimated PCD: 2024-12-31
Product
Digoxin